Centessa Pharmaceuticals plc
HealthcareNASDAQ:CNTA · NASDAQ Global Select
-$0.05 today
Vol 1.12M · Avg 2.59M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$250.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.78, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.0M | $0 -100.0% | $6.9M | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $15.0M | $0 -100.0% | $6.9M | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% | — | 100.0% | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $172.2M +14.6% | $150.2M +20.8% | $124.4M -19.8% | $155.1M +61.0% | $96.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $50.5M -0.7% | $50.8M -5.4% | $53.7M -2.7% | $55.2M +28.3% | $43.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $222.7M +10.8% | $201.1M +12.9% | $178.1M -16.1% | $212.3M -43.4% | $374.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 -100.0% | $942.0K +16.3% | $810.0K +518.3% | $131.0K +285.3% | $34.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$184.3M +17.0% | -$221.9M -34.1% | -$165.4M +21.1% | -$209.5M -50.4% | -$139.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -1228.4% | — | -2413.9% | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$207.7M -3.3% | -$201.1M -17.4% | -$171.3M +19.3% | -$212.3M +43.4% | -$374.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -1384.6% | — | -2499.4% | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $20.5M +46.5% | $14.0M +33.8% | $10.5M +4193.4% | $244.0K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $11.5M +13.6% | $10.1M +1.9% | $9.9M +36.1% | $7.3M +185.5% | $2.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $12.0M +137.6% | -$31.9M -555.8% | -$4.9M -3.6% | -$4.7M +32.2% | -$6.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$195.7M +16.0% | -$232.9M -32.2% | -$176.1M +18.8% | -$217.0M +43.2% | -$381.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -1304.8% | — | -2570.3% | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.8M -36.0% | $2.8M +111.4% | -$25.1M -3254.2% | -$747.0K -755.3% | $114.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$197.5M +16.2% | -$235.8M -56.0% | -$151.1M +30.1% | -$216.2M +43.4% | -$381.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | -1316.9% | — | -2204.7% | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +29.1% | -$2 -31.2% | -$2 +32.0% | -$2 +45.5% | -$4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +29.1% | -$2 -31.2% | -$2 +32.0% | -$2 +45.5% | -$4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $135.7M +18.6% | $114.5M +19.0% | $96.2M +3.0% | $93.4M +3.8% | $90.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $135.7M +18.6% | $114.5M +19.0% | $96.2M +3.0% | $93.4M +3.8% | $90.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.63B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.25B
Celcuity Inc.
NASDAQ:CELC
$4.32B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.11B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Ascentage Pharma Group International
NASDAQ:AAPG
$409.04M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CNTA generate?
Centessa Pharmaceuticals plc (CNTA) reported $15.00M of revenue in fiscal 2025.
Is CNTA profitable?
Centessa Pharmaceuticals plc (CNTA) reported -$197,532,000.00 of net income, with a net margin of -1316.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.